Vymada 50mg Tablet

PRODUCT INTRODUCTION

Vymada 50mg Tablet, scientifically known as Sacubitril/Valsartan, combines two active ingredients to effectively manage heart failure. This medication is primarily designed to address chronic heart failure with reduced ejection fraction (HFrEF) in adult patients who have been stabilized after experiencing symptoms and require additional treatment to enhance cardiac function.

Sacubitril, an inhibitor of neprilysin, works by increasing the levels of beneficial peptides such as natriuretic peptides, which help to dilate blood vessels and decrease blood pressure. Valsartan, an angiotensin receptor blocker (ARB), blocks the effects of angiotensin II, a substance that causes blood vessels to constrict, thereby reducing blood pressure and the workload on the heart.

2. USES OF Vymada 50mg Tablet

Vymada 50mg Tablet is prescribed for the following conditions:

• Chronic Heart Failure (CHF) with Reduced Ejection Fraction: It is used in adult patients to reduce the risk of cardiovascular death and hospitalization due to heart failure. It is typically prescribed when standard therapies for heart failure are inadequate.

3. BENEFITS OF Vymada 50mg Tablet

• Improved Cardiovascular Outcomes: Clinical studies have shown that Vymada 50mg Tablet significantly reduces the risk of cardiovascular death and hospitalization compared to conventional therapies alone.
• Symptomatic Relief: Patients often experience improved symptoms of heart failure, such as reduced shortness of breath, fatigue, and fluid retention, leading to an enhanced quality of life.
• Enhanced Exercise Tolerance: The medication can improve the ability to exercise and engage in daily activities by optimizing cardiac function and reducing the strain on the heart.

4. SIDE EFFECTS OF Vymada 50mg Tablet

While Vymada 50mg Tablet offers substantial benefits, it may also cause certain side effects, which can vary in severity from mild to severe. Common side effects include:

• Hypotension (Low Blood Pressure): Due to the blood pressure-lowering effects of both sacubitril and valsartan, some patients may experience dizziness, lightheadedness, or fainting, especially when standing up suddenly.
• Hyperkalemia (High Potassium Levels): This can occur, particularly in patients with pre-existing kidney problems or those taking potassium-sparing diuretics or supplements.
• Renal Impairment: Some individuals may experience a decline in kidney function, necessitating careful monitoring of renal parameters during treatment.
• Angioedema: Although rare, sacubitril/valsartan can rarely cause swelling of the face, lips, tongue, or throat, which requires immediate medical attention.
• Cough: A persistent cough has been reported in some patients, although less frequently than with ACE inhibitors.

Disclaimer